Videos
Watch our experts break down complex topics and suggest ways to adjust your business. Gain clarity, step-by-step.
Embedding Patient-Centric Principles in Research, Quality, and Care Delivery
In this installment of our 2023 Top Trends in HEOR series, Avalere experts dive into Trend #5, patient engagement and centricity in healthcare decision making.
2023 Top Trends in Health Economics and Outcomes Research
Avalere identified the top trends in health economics and outcomes research in 2023 and beyond. In this video, Avalere experts dive into a few of the key trends in HEOR that are significantly shaping the landscape.
Maximizing Access & Uptake for Digital Health Technologies
Significant investment and attention has been paid to the digital health space in recent years as a promising frontier in improving care for patients. In this video, Avalere experts discuss several solutions, including increased, streamlined stakeholder collaboration, improvements in evidence generation, established value assessment frameworks, and identification of a clear reimbursement pathway that can create a path for more optimal access, uptake, and utilization.
Unpacking the Implications of the Negotiated Drug List, Part 2
In Part 2 of our video series on the negotiated drug list, Avalere experts discuss topics including effectiveness measures that will inform CMS’s maximum fair price determinations, evidence generation strategies for manufacturers with products that have been selected for negotiation, or that are eligible for selection in the future, and CMS’s definition of therapeutic alternatives.
Spotlight on Avalere’s Evidence and Strategy Practice
Laura Housman, Avalere’s Evidence and Strategy Practice Director, discusses her past experience, trends in real-world evidence, and the role of data in advocating for the patient voice.
Unpacking the Implications of the Negotiated Drug List, Part 1
Delve into the far-reaching implications of the recently announced negotiated drug list as Avalere experts provide insights and answers to pressing questions surrounding CMS's landmark decision on Part D drug pricing and its impact on manufacturers, patients, and the future healthcare landscape.
Patient Support Perspective for 2023 and Beyond
Avalere experts delve into the dynamic patient assistance program landscape, including copay accumulators and maximizers, alternative funding initiatives, and the repercussions of policy shifts such as the Inflation Reduction Act and state-level copay accumulator bans.
Navigating Major Policy Changes: Insights for Medicare Advantage Plans
Avalere experts explore how key policy changes, such as the Risk Adjustment Data Validation final rule, Inflation Reduction Act, and Medicare Advantage payment shifts, are shaping the landscape for health plans.
Understanding the Medicaid Drug Rebate Program Proposed Rule
Avalere's policy experts discuss the key provisions and potential impacts of the recent CMS proposed rule related to the Medicaid drug rebate program (MDRP.)
RSV Prevention, Part V: Where Are We Now?
In the fifth installment of our Respiratory Syncytial Virus (RSV) prevention series, Avalere experts discuss updates to the RSV prevention landscape, including newly approved products and recent Advisory Committee on Immunization Practices (ACIP) meeting discussions.
Congressional Debate Over PBM Legislation
Avalere experts discuss Congress’ ongoing consideration of pharmacy benefit manager (PBM) legislation.
Innovations in Kidney Care
Avalere experts discuss trends and advancements in the kidney disease space, including payment models, digital health interventions, and key considerations for manufacturers.
IRA Impacts on Evidence and Strategy
Ahead of the Asembia and ISPOR 2023 conferences, Avalere experts discuss the increasing importance of value and evidence strategies as part of Inflation Reduction Act (IRA) implementation planning.
IRA Impacts on Patient Access
Ahead of Asembia 2023, Avalere experts discuss how the IRA and other regulatory changes will impact patient access and affordability.
Evidence and Value Under the Inflation Reduction Act
In our Outlook 2023 webinar, Avalere expert Michael Ciarametaro discussed how evidence generation requirements will differ under the Inflation Reduction Act (IRA.)
IRA Policy Changes: Planning for Life Sciences
The Inflation Reduction Act (IRA) brings some of the biggest changes affecting the pharmaceutical industry in the last decade. Avalere expert Megan West discusses how these shifts will impact pharmaceutical organizations and how Avalere can support in developing strategies to mitigate risk and identify opportunities across the product lifecycle.
Medicare Advantage and Part D Advance Notice: Proposed Payment Changes
Avalere expert Sean Creighton explains key policy changes proposed in the Advance Notice for Medicare Advantage and Part D Payment for Plan Year 2024.
The Future of Patient-Centric Value
Avalere experts Amanda Napoles and Shelby Harrington share recommendations for shifting to patient-centered value during our 2023 Outlook webinar.
Enhancing Oncology Model (EOM) Participation
Avalere expert Maddi Davidson discussed key EOM methods changes that will impact practice decision making.
Plan and Beneficiary Responses to IRA Policies
Avalere expert Rebecca Yip discussed plan and beneficiary responses to IRA policies during our 2023 Outlook webinar.